JP7523146B2 - Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体 - Google Patents

Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体 Download PDF

Info

Publication number
JP7523146B2
JP7523146B2 JP2021572425A JP2021572425A JP7523146B2 JP 7523146 B2 JP7523146 B2 JP 7523146B2 JP 2021572425 A JP2021572425 A JP 2021572425A JP 2021572425 A JP2021572425 A JP 2021572425A JP 7523146 B2 JP7523146 B2 JP 7523146B2
Authority
JP
Japan
Prior art keywords
pyridin
trifluoromethyl
pyrrolo
oxadiazol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021572425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535290A5 (https=
JP2022535290A (ja
Inventor
カルセリャール・ゴンサレス，エレナ
オルテガ・ムニョス，アルベルト
サラス・ソラナ，ホルヘ
Original Assignee
オリゾン・ゲノミクス・ソシエダッド・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリゾン・ゲノミクス・ソシエダッド・アノニマ filed Critical オリゾン・ゲノミクス・ソシエダッド・アノニマ
Publication of JP2022535290A publication Critical patent/JP2022535290A/ja
Publication of JP2022535290A5 publication Critical patent/JP2022535290A5/ja
Application granted granted Critical
Publication of JP7523146B2 publication Critical patent/JP7523146B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021572425A 2019-06-06 2020-06-05 Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体 Active JP7523146B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382475.2 2019-06-06
EP19382475 2019-06-06
EP19383221.9 2019-12-31
EP19383221 2019-12-31
PCT/EP2020/065658 WO2020245381A1 (en) 2019-06-06 2020-06-05 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors

Publications (3)

Publication Number Publication Date
JP2022535290A JP2022535290A (ja) 2022-08-05
JP2022535290A5 JP2022535290A5 (https=) 2023-06-13
JP7523146B2 true JP7523146B2 (ja) 2024-07-26

Family

ID=71083614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572425A Active JP7523146B2 (ja) 2019-06-06 2020-06-05 Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体

Country Status (7)

Country Link
US (1) US12522598B2 (https=)
EP (1) EP3980416B1 (https=)
JP (1) JP7523146B2 (https=)
CN (1) CN114206868B (https=)
CA (1) CA3142435A1 (https=)
MX (1) MX2021014918A (https=)
WO (1) WO2020245381A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533721A (ja) 2011-11-28 2014-12-15 ノバルティス アーゲー 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JP7369458B2 (ja) 2017-12-05 2023-10-26 オリソン ヘノミクス，ソシエダ アノニマ ヒストンデアセチラーゼ６阻害剤としての１，２，４－オキサジアゾール誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101618B2 (en) 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
US20100136024A1 (en) 2008-11-14 2010-06-03 Bartels Stephen P Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
US10081624B2 (en) 2014-08-26 2018-09-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2017014170A1 (ja) 2015-07-17 2018-04-26 武田薬品工業株式会社 複素環化合物
AU2016297362B2 (en) 2015-07-17 2020-04-16 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as HDAC inhibitors
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
WO2017161033A1 (en) 2016-03-15 2017-09-21 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017222950A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018118781A1 (en) 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533721A (ja) 2011-11-28 2014-12-15 ノバルティス アーゲー 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222951A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JP7369458B2 (ja) 2017-12-05 2023-10-26 オリソン ヘノミクス，ソシエダ アノニマ ヒストンデアセチラーゼ６阻害剤としての１，２，４－オキサジアゾール誘導体

Also Published As

Publication number Publication date
MX2021014918A (es) 2022-06-27
US12522598B2 (en) 2026-01-13
CN114206868B (zh) 2025-02-25
WO2020245381A1 (en) 2020-12-10
JP2022535290A (ja) 2022-08-05
CN114206868A (zh) 2022-03-18
EP3980416A1 (en) 2022-04-13
US20220298156A1 (en) 2022-09-22
CA3142435A1 (en) 2020-12-10
EP3980416B1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
CN111406054B (zh) 作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物
JP7175888B2 (ja) 選択的ｈｄａｃ１、２阻害剤としてのピペラジン誘導体
CA3158951A1 (en) 4-substituted aminoisoquinoline derivatives
TW200417546A (en) New compounds
JP7523146B2 (ja) Ｈｄａｃ６阻害薬としての３－（２－（ヘテロアリール）－ピリジン－４－イル）－５－（トリフルオロメチル）－１，２，４－オキサジアゾール誘導体
KR20090024110A (ko) 키나제 억제제로서의 ３-치환된 Ｎ-(아릴- 또는 헤테로아릴)-피라졸로[１,５-ａ]피리미딘
JP7195436B2 (ja) バニン阻害剤としての複素芳香族化合物
EP3027613B1 (en) Pyrroloquinoline derivatives as 5-ht6 antagonists, preparation method and use thereof
CA3112330A1 (en) Hdac1,2 inhibitors
JP6033788B2 (ja) 置換されたメチルアミン、セロトニン５−ｈｔ６受容体アンタゴニスト、製造のための方法及びその使用
WO2023085432A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２薬
KR20090007391A (ko) 키나제 억제제로서의 ３-비치환된 Ｎ-(아릴- 또는 헤테로아릴)-피라졸로[１,５-ａ]피리미딘
CN109422753A (zh) 一类具有抑制并降解酪氨酸蛋白激酶jak1或jak2活性的化合物
EP3269714A1 (en) Inhibitors of tryptophan 2,3-dioxygenase
US20050282811A1 (en) Diazabicyclic histamine-3 receptor antagonists
RU2797613C2 (ru) Производные 1,2,4-оксадиазола в качестве ингибиторов гистондезацетилазы 6
TWI692476B (zh) 環丁基-咪唑啶酮化合物
BR112020010534B1 (pt) Derivados de 1,2,4-oxadiazol, seus usos como inibidores de histona desacetilase 6 e composição farmacêutica compreendendo os mesmos
BRPI0619955A2 (pt) derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
HK40125992A (zh) 神经营养受体酪氨酸激酶(ntrk)抑制剂及其使用方法
CN114426541A (zh) 氮杂芳基化合物及其用途
EA045146B1 (ru) Гетероароматические соединения в качестве ингибиторов ванина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240708

R150 Certificate of patent or registration of utility model

Ref document number: 7523146

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150